[{"id":"69c25f97-9257-4b4a-bda9-abd8b68285ba","acronym":"ENHANCE","url":"https://clinicaltrials.gov/study/NCT05275374","created_at":"2022-03-11T15:53:39.251Z","updated_at":"2024-07-02T16:35:22.552Z","phase":"Phase 1/2","brief_title":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation","source_id_and_acronym":"NCT05275374 - ENHANCE","lead_sponsor":"Xynomic Pharmaceuticals, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • XP-102"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 221","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-23"}]